One of the targeted recipients, TiBA Biotech, had an agreement worth USD 750,000 from Bard, which was to end on October 30. The company developed therapeutics based on RNAI for the H1N1 flu, also known as pig flu. RNAI is tiny for RNA interference and refers to compact pieces of RNA, which can close the production of specific proteins. The approach has been well examined, and several RNAI -based drugs are on the market. The first was approved in 2018 to treat nerve damage caused by a sporadic disease called hereditary amyloidosis through extermination.
The cancellation of the contract was a surprise for TiBA, which received the order of detention on August 5, which did not refer to the wind, the development of MRNA Bard vaccines. “Our project does not include the development of the MRNA product and is a therapeutics rather than a vaccine,” said Jasdave Chahal, the main scientific officer of TIBY via e -mail.
Government agreements often include specific milestones that contractors must achieve to receive financing and continue their projects. Tiba claims that his project has achieved his goals so far and was almost completed.
Also among the canceled contracts was the 750,000 USD award for Emory University for transformation based on mRNA antiviral treatment of flu and Covid into a inhaled, desiccated powder preparation. The project did not include the development of the vaccine. “Unfortunately, we don’t have much insight into the reference of the subsidy,” said Emory spokesman Brian Katzowitz We -Mail.
The cuts are in line with Kennedy’s desire to depriorize research on infectious diseases, although Experts warned that they could cause the US to be more exposed to future pandems.
Despite the reduction of tests of infectious diseases related to RNA, the administration expressed enthusiasm about some unrestrained studies involving MRNA.
In January, shortly after the office, President Trump announced the joint venture of Opeli, Oracle and Softbank called Stargate to invest up to $ 500 billion in AI infrastructure. At that time, the CEO of Oracle, Larry Ellison, uttered AI’s potential to create personalized MRNA based on cancer vaccines.
IN August 12 OP-ED At Washington Post, the director of the National Institutes of Health Jay Bhattacharya recognized the promise of MRNA. “I do not question its potential. In the future it can still provide a breakthrough in the treatment of diseases such as cancer, and HHS still invests in current research on oncology applications and other complex diseases,” he wrote.
Unlike his boss, Bhattacharya says that he does not believe that MRNA vaccines caused mass damage. However, he says that the reason for stopping the research of MRNA vaccines is that the platform has lost public trust – the justification that deviates from Kennedy.
However, MRNA can be more accepted when it comes to treating very diseased patients with genetic disorders.
At the beginning of this year, regulatory bodies in the FDA Pentec to Personalized Treatment of the Edition of the Baby gene editions named KJ Muldoon with a sporadic and life -threatening liver disease. Created in just six months, it uses MRNA to provide elements of editions of the liver genes. Non -standard treatment of gene edition for effective patient treatment was used for the first time.
In June, FDA Commissioner Marty Makary he praised the achievement ON His podcastcalling this “a kind of great win for medical sciences” and in FDA Round table Makary said that the agency would continue to facilitate the regulatory process for this type of product.
Scientists standing behind a non -standard gene treatment plan for the same approach for a larger number of patients, and recently met with the FDA about a clinical trial proposal. “FDA was very positive about the proposal and effectively gave us green light to continue our work,” says Kiran Musnuru, professor of translational research at the University of Pennsylvania and a children’s hospital in Philadelphia.
The team has another meeting with the FDA for a month or two to discuss the extension of the Platform concept outside a single disease or a single gene to a wider group of disorders. “We’ll see how it goes,” he says.